Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals
In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients
R. Lee Clark to Retire; Texas Starts Search for Successor
Drugs Available To Investigators Centers to Monitor Them Are Listed
FDA’s Young Still Not Satisfied With Distribution Plan
Tobacco Council Announces Awards
FDA Adopts Final Diagnostics X-Ray Rule Amendment
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed
